Endo S, Kida A, Sawada U, Sugitani M, Furusaka T, Yamada Y, Iida H, Sakai F, Shigihara S, Niwa H, Yamazaki T, Kura Y, Kikuchi K
Department of ORL, Nihon University, School of Medicine, Tokyo, Japan.
Acta Otolaryngol Suppl. 1996;523:263-6.
Data of 38 patients with primary tonsil lymphoma, treated during the past 14 years was analysed. All cases were non-Hodgkin lymphomas. There were 11 patients with Stage 1, 14 with Stage II, 8 with Stage III, and 4 with Stage IV tonsillar lymphomas. The applied chemotherapies were CHOP or MACOP-B regimen. The overall 5-year survival rate was 64.4%. Further analysis of the intermediate grade group showed that 5-year survival rates were 72.7%) for patients younger than 60 years old, in contrast to 35.0% for patients aged 60 or older (p 0.0049). Five-year survival rates were 100%) for Stage I, 32.4% for Stage II, 55.6% for Stage III, and 100%) for Stage IV patients (p = 0.0878). In patients with Stage II tonsillar lymphomas, 5-year survival rates were below 100% for CHOP regimen, 100% for MACOP-B regimen, 66.7% for radiation alone, and 0% for radiation followed by chemotherapy (p = 0.1966). In patients with Stage III tonsillar lymphomas, 5-year survival rates were below 100% for MACOP-B regimen, and 0% for initial radiation followed by chemotherapy (p = 0.2568). The factors influencing survival were age, stage, and treatment modality. For Stage I patients without bulky mass, radiation therapy is sufficient. For Stage II patients or Stage I patients with a bulky mass, CHOP regimen (followed by radiation) is the choice of treatment. For Stage III or IV patients,, MACOP-B regimen is promising.
分析了过去14年中接受治疗的38例原发性扁桃体淋巴瘤患者的数据。所有病例均为非霍奇金淋巴瘤。1期患者11例，II期患者14例，III期患者8例，IV期扁桃体淋巴瘤患者4例。应用的化疗方案为CHOP或MACOP - B方案。总体5年生存率为64.4%。对中级别组的进一步分析表明，60岁以下患者的5年生存率为72.7%，而60岁及以上患者为35.0%（p = 0.0049）。I期患者的5年生存率为100%，II期为32.4%，III期为55.6%，IV期患者为100%（p = 0.0878）。在II期扁桃体淋巴瘤患者中，CHOP方案的5年生存率低于100%，MACOP - B方案为100%，单纯放疗为66.7%，放疗后化疗为0%（p = 0.1966）。在III期扁桃体淋巴瘤患者中，MACOP - B方案的5年生存率低于100%，初始放疗后化疗为0%（p = 0.2568）。影响生存的因素包括年龄、分期和治疗方式。对于无巨大肿块的I期患者，放疗就足够了。对于II期患者或有巨大肿块的I期患者，CHOP方案（随后放疗）是治疗选择。对于III期或IV期患者，MACOP - B方案很有前景。
